Beta Bionics faces a class action lawsuit for allegedly misleading investors about the safety and effectiveness of its iLet Bionic Pancreas insulin pump. The company claimed FDA concerns were minor and unrelated to device safety, but the FDA's warning letter revealed serious device malfunctions causing dangerous insulin overdoses and life-threatening events. The stock price dropped from $31.99 to $12.89 after these disclosures. Investors who bought Beta Bionics stock between July 30, 2025, and February 24, 2026, may join the lawsuit before the November 3, 2026 deadline.
Vannor introduced an agentic marketing model featuring autonomous AI agents that independently manage marketing tasks from research to content publication and optimization. Running on Vannor-owned NVIDIA AI hardware, these agents increased the compan...
A crypto whale recently withdrew 440,249 WLD tokens valued at nearly $250,000 from the Bybit exchange using a newly created wallet. This withdrawal happened about four hours before the report was published. Approximately one week earlier, the whale h...
U.S. spot Ethereum ETFs experienced significant net outflows totaling $542.2 million over five trading days ending October 9, coinciding with Ether's price falling below $2,500. The withdrawals occurred over nine consecutive sessions, with BlackRock’...
Ethereum's price has fallen below its 50-day simple moving average, trading near $2,491 and down over 7% in the past week. U.S. spot Ethereum ETFs experienced their largest weekly outflow since January, with about $542 million withdrawn, mainly from ...
Chevron has maintained a 39-year streak of raising dividends through various oil market challenges, including crashes and the pandemic. Despite a first-quarter 2026 cash flow shortfall covered by the balance sheet, the company recovered strongly in t...
